ROIVANT SCIENCES LTD. Income (Loss) from Equity Method Investments
ROIVANT SCIENCES LTD. (ROIV) reported Income (Loss) from Equity Method Investments of $0 for the 12-month period ending 2022-03-31, per its 10-K filed 2022-06-28.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2022-06-28
- ROIVANT SCIENCES LTD. income (loss) from equity method investments for the quarter ending 2022-03-31 was $0.00.
- ROIVANT SCIENCES LTD. income (loss) from equity method investments for the quarter ending 2021-12-31 was $0.00.
- ROIVANT SCIENCES LTD. income (loss) from equity method investments for the quarter ending 2021-09-30 was $0.00.
- ROIVANT SCIENCES LTD. income (loss) from equity method investments for the quarter ending 2021-06-30 was $0.00.
- ROIVANT SCIENCES LTD. income (loss) from equity method investments for fiscal 2022 was $0.00.
- ROIVANT SCIENCES LTD. income (loss) from equity method investments for fiscal 2021 was -$3.75M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2022-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | $0.00 derived: sum of 2 quarters · filed 2022-06-28 | $0.00 derived: sum of 3 quarters · filed 2022-06-28 | $0.00 10-K · filed 2022-06-28 |
| 2021-12-31 | $0.00 10-Q · filed 2022-02-14 | $0.00 derived: sum of 2 quarters · filed 2022-02-14 | $0.00 10-Q · filed 2022-02-14 | $0.00 derived: sum of 4 quarters · filed 2022-06-28 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | $0.00 derived: sum of 3 quarters · filed 2022-06-28 | $0.00 derived: sum of 4 quarters · filed 2022-06-28 |
| 2021-06-30 | $0.00 10-Q · filed 2021-09-21 | $0.00 derived: sum of 2 quarters · filed 2022-06-28 | $0.00 derived: sum of 3 quarters · filed 2022-06-28 | $0.00 derived: sum of 4 quarters · filed 2022-06-28 |
| 2021-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | $0.00 derived: sum of 2 quarters · filed 2022-06-28 | $0.00 derived: sum of 3 quarters · filed 2022-06-28 | -$3.75M 10-K · filed 2022-06-28 |
| 2020-12-31 | $0.00 10-Q · filed 2022-02-14 | $0.00 derived: sum of 2 quarters · filed 2022-02-14 | -$3.75M 10-Q · filed 2022-02-14 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 | -$3.75M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$3.75M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |